Cargando…
Alternative pre-approved and novel therapies for the treatment of anthrax
BACKGROUND: Bacillus anthracis, the causative agent of anthrax, is a spore forming and toxin producing rod-shaped bacterium that is classified as a category A bioterror agent. This pathogenic microbe can be transmitted to both animals and humans. Clinical presentation depends on the route of entry (...
Autores principales: | Head, Breanne M., Rubinstein, Ethan, Meyers, Adrienne F. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094018/ https://www.ncbi.nlm.nih.gov/pubmed/27809794 http://dx.doi.org/10.1186/s12879-016-1951-y |
Ejemplares similares
-
Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule”
por: Tsai, Chia-Wei, et al.
Publicado: (2015) -
Monoclonal Antibody Therapies against Anthrax
por: Chen, Zhaochun, et al.
Publicado: (2011) -
Pre-Columbian Origins for North American Anthrax
por: Kenefic, Leo J., et al.
Publicado: (2009) -
Treatment of Anthrax
Publicado: (1893) -
Human Anthrax: Update of the Diagnosis and Treatment
por: Doganay, Mehmet, et al.
Publicado: (2023)